Rosuvastain Calcium Tablet, Film Coated
NDC Package 62135-692-90
Package Information
Rosuvastain Calcium tablets is rosuvastatin tablets are indicated:To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor.As an adjunct to diet to: Reduce LDL-C in adults with primary hyperlipidemia.Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults.Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia.Hypertriglyceridemia. This formulation utilizes a tablet, film coated delivery system. Marketed by Chartwell Rx, Llc, this product is identified by NDC 62135-692 and is authorized under FDA application ANDA079168.
Identification & Billing
- RxCUI: 859419 - rosuvastatin calcium 40 MG Oral Tablet
- RxCUI: 859424 - rosuvastatin calcium 5 MG Oral Tablet
- RxCUI: 859747 - rosuvastatin calcium 10 MG Oral Tablet
- RxCUI: 859751 - rosuvastatin calcium 20 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62135 - Chartwell Rx, Llc
- 62135-692 - Rosuvastain Calcium
- 62135-692-90 - 90 TABLET, FILM COATED in 1 BOTTLE
- 62135-692 - Rosuvastain Calcium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62135-692-90 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Rosuvastain Calcium, a human prescription drug labeled by Chartwell Rx, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 90 billable units per package. This tablet, film coated is formulated for oral use and contains rosuvastatin calcium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Chartwell Rx, Llc on July 19, 2016. The current certification is valid through December 31, 2027.
How is this Chartwell Rx, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62135069290. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.